Skip Navigation

JNCI Journal of the National Cancer Institute 2001 93(2):79; doi:10.1093/jnci/93.2.79
© 2001 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 93, No. 2, 79, January 17, 2001
© 2001 Oxford University Press

IN THIS ISSUE

Treatment of Patients With Small Breast Cancers

Uncertainty about prognosis and treatment of axillary lymph node-negative patients with estrogen receptor (ER)-negative or ER-positive breast cancers of 1 cm or less prompted Fisher et al. (p. 112) to analyze data from five National Surgical Adjuvant Breast and Bowel Project randomized clinical trials. They looked at relapse-free survival (RFS) and overall survival after 8 years of follow-up. Women with ER-negative tumors who received either surgery or surgery and chemotherapy had similar overall survival; however, those who also received chemotherapy had better RFS (81% versus 90%). Women with ER-positive tumors . . . [Full Text of this Article]

Radiation Damage and Skin Biomarkers

Estimated Nicotine Intakes and Toxin Exposure in Smokers

Breast Cancer Risk in Ataxia-Telangiectasia Carriers

Quality of Informed Consent


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?